Nalaganje...
Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) frequently express CD19, CD20 and CD22 on the cell surfaces. Immunotherapeutic agents including antibodies and chimeric antigen receptor T cells are widely studied in clinical trials. Several antibody-drug conjugates (ADC) have...
Shranjeno v:
| izdano v: | Biomark Res |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6458768/ https://ncbi.nlm.nih.gov/pubmed/31011424 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-019-0160-4 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|